JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB209899

Anti-AKR1C3+AKR1C4 antibody [EPR16726]

Be the first to review this product! Submit a review

|

(10 Publications)

Rabbit Recombinant Monoclonal AKR1C3 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human samples. Cited in 10 publications.

View Alternative Names

DDH1, HSD17B5, KIAA0119, PGFS, AKR1C3, Aldo-keto reductase family 1 member C3, 17-beta-hydroxysteroid dehydrogenase type 5, 3-alpha-hydroxysteroid dehydrogenase type 2, Chlordecone reductase homolog HAKRb, Dihydrodiol dehydrogenase 3, Dihydrodiol dehydrogenase type I, HA1753, Prostaglandin F synthase, Testosterone 17-beta-dehydrogenase 5, 17-beta-HSD 5, 3-alpha-HSD type 2, DD-3, DD3

7 Images
Immunocytochemistry/ Immunofluorescence - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized A549 (Human lung carcinoma cell line) cells labeling AKR1C3 with ab209899 at 1/100 dilution followed by Goat anti-Rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing cytoplasmic staining on A549 cell line.

The nuclear counterstain is DAPI (blue).

Tubulin is detected with Anti-alpha Tubulin antibody - Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG (Alexa Fluor®594) preadsorbed (ab150120) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab209899 at 1/100 dilution followed by ab150120 at 1/1000 dilution.

-ve control 2 : ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.

Flow Cytometry (Intracellular) - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed A549 (Human lung carcinoma cell line) cells labeling AKR1C3with ab209899 at 1/70 dilution (red) compared with a Rabbit IgG,monoclonal- Isotype control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti Rabbit IgG (Alexa Fluor® 488) at 1/500 dilution was used as the secondary antibody.

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized HepG2 (Human liver hepatocellular carcinoma cell line) cells labeling AKR1C3 with ab209899 at 1/100 dilution followed by Goat Anti-Rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing cytoplasmic staining on HepG2 cell line.

The nuclear counterstain is DAPI (blue).

Tubulin is detected with Anti-alpha Tubulin antibody - Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG (AlexaFluor®594) preadsorbed (ab150120) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab209899 at 1/100 dilution followed by ab150120 at 1/1000 dilution.

-ve control 2 : ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.

Immunoprecipitation - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • IP

Supplier Data

Immunoprecipitation - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

AKR1C3 was immunoprecipitated from 1mg of HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate with ab209899 at 1/30 dilution.

Western blot was performed from the immunoprecipitate using ab209899 at 1/1000 dilution.

VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.

Lane 1 : HepG2 whole cell lysate, 10μg (Input).

Lane 2 : ab209899 IP in HepG2 whole cell lysate.

Lane 3 : Rabbit IgG,monoclonal - Isotype Control (ab172730) instead of ab209899 in HepG2 whole cell lysate.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 1 second.

All lanes:

Immunoprecipitation - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (ab209899)

Predicted band size: 37 kDa

false

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • WB

Supplier Data

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (ab209899) at 1/2000 dilution

Lane 1:

HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate (control) at 10 µg

Lane 2:

HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 10 µg with AKR1C3 peptide on the membrane

Lane 3:

HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate at 10 µg with AKR1C4 peptide on the membrane

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 37 kDa

Observed band size: 37 kDa

false

Exposure time: 3min

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • WB

Lab

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Blocking and dilution buffer : 5% NFDM/TBST

Lanes 1 - 4:

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (ab209899) at 1/1000 dilution

Lanes 1 - 4:

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] - BSA and Azide free (<a href='/en-us/products/primary-antibodies/akr1c3akr1c4-antibody-epr16726-bsa-and-azide-free-ab251511'>ab251511</a>) at 1/1000 dilution

Lane 1:

His-tagged human AKR1C1 recombinant protein, full-length

Lane 2:

His-tagged human AKR1C2 recombinant protein, full-length

Lane 3:

His-tagged human AKR1C3 recombinant protein, full-length

Lane 4:

His-tagged human AKR1C4 recombinant protein, full-length

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/20000 dilution

Observed band size: 39 kDa

false

Exposure time: 10s

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)
  • WB

Supplier Data

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : Lane 1/3 : 2 seconds; Lane 2 : 30 seconds.

Lanes 1 - 2:

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (ab209899) at 1/1000 dilution

Lane 3:

Western blot - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (ab209899) at 1/5000 dilution

Lane 1:

Human fetal kidney lysate at 20 µg

Lane 2:

MOLT-4 (Human lymphoblastic leukemia cell line) whole cell lysate at 20 µg

Lane 3:

A549 (Human lung carcinoma cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

Predicted band size: 37 kDa,90 kDa

Observed band size: 37 kDa

false

  • Carrier free

    Anti-AKR1C3+AKR1C4 antibody [EPR16726] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR16726

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

Flow Cyt (Intra), IP, ICC/IF, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/70", "FlowCytIntra-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The proteins AKR1C3 and AKR1C4 also known as Aldo-Keto Reductase Family 1 Member C3 and C4 are reductases involved in the metabolism of steroids prostaglandins and xenobiotics. AKR1C3 has a molecular mass of approximately 37 kDa while AKR1C4 is slightly larger at around 37.2 kDa. These proteins are expressed mainly in the liver but you can also find AKR1C3 in adrenal glands and prostate tissues. Current research shows their functions in enzymatic reduction processes significantly affect hormone conversion and lipid metabolism.
Biological function summary

The proteins AKR1C3 and AKR1C4 have significant roles in steroid hormone metabolism. They do not form a part of any larger complex but act independently to catalyze the conversion of active androgens and estrogens. AKR1C3 for example converts androstenedione to testosterone and estrone to estradiol affecting steroid balance in tissues. Meanwhile AKR1C4 primarily catalyzes the reduction of bile acid intermediates assisting in maintaining liver health and function.

Pathways

AKR1C3 and AKR1C4 operate closely in metabolic pathways involving steroid metabolism and bile acid biosynthesis. In the steroid metabolism pathway they associate with other enzymes like 5α-reductase and CYP19A1 (aromatase) to regulate the conversion and amplification of steroid hormones. In bile acid biosynthesis AKR1C4 works conjointly with enzymes like CYP7A1 playing a significant role in processing cholesterol substrates into bile acids important for lipid digestion and absorption.

AKR1C3 and AKR1C4 have associations with conditions such as prostate cancer and liver disease. AKR1C3's upregulation correlates with prostate cancer progression by influencing androgen receptor activation. It relates to enzymes like CYP17A1 which share involvement in androgen biosynthesis. Meanwhile AKR1C4 plays a role in liver diseases such as cholestasis and is thought to interact with proteins involved in bile transport and synthesis potentially impacting pathological bile acid accumulation. Understanding these interactions helps inform therapeutic strategies targeting hormone and bile acid-related disorders.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone (PubMed : 10622721, PubMed : 11165022, PubMed : 7650035, PubMed : 9415401, PubMed : 9927279). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed : 11165022, PubMed : 14672942). Acts preferentially as a 17-ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone (PubMed : 20036328). Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and estrone to 17beta-estradiol (PubMed : 10622721, PubMed : 10998348, PubMed : 11165022, PubMed : 15047184, PubMed : 19010934, PubMed : 20036328). Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed : 10557352, PubMed : 10998348, PubMed : 11165022, PubMed : 14672942, PubMed : 7650035, PubMed : 9415401). Also displays retinaldehyde reductase activity toward 9-cis-retinal (PubMed : 21851338).
See full target information AKR1C3

Additional targets

AKR1C4

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

iScience 28:111808 PubMed39995859

2025

Identification of meibomian gland testosterone metabolites produced by tissue-intrinsic intracrine deactivation activity.

Applications

Unspecified application

Species

Unspecified reactive species

Khanh Tien Nguyen Pham,Takahito Miyake,Tomo Suzuki,Shigeru Kinoshita,Yuki Hamada,Hikari Uehara,Mamiko Machida,Takeshi Nakajima,Emi Hasegawa,Masao Doi

Theranostics 14:7623-7644 PubMed39659569

2024

Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer's disease phenotypes.

Applications

Unspecified application

Species

Unspecified reactive species

Dong Peng,Tingting Liu,Huahui Lu,Lei Zhang,Hongxia Chen,Yadong Huang,Bo Hu,Qihao Zhang

Aging 15:3807-3825 PubMed37166429

2023

Identification and validation of metabolism-related genes signature and immune infiltration landscape of rheumatoid arthritis based on machine learning.

Applications

Unspecified application

Species

Unspecified reactive species

Zhaoyang Guo,Yuanye Ma,Yaqing Wang,Hongfei Xiang,Huifei Cui,Zuoran Fan,Youfu Zhu,Dongming Xing,Bohua Chen,Hao Tao,Zhu Guo,Xiaolin Wu

Endocrinology 164: PubMed36799021

2023

Insulin-Induced AKR1C3 Induces Fatty Acid Synthase in a Model of Human PCOS Adipocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Ryan D Paulukinas,Trevor M Penning

Journal of nanobiotechnology 21:55 PubMed36803994

2023

Hyaluronic acid-FGF2-derived peptide bioconjugates for suppression of FGFR2 and AR simultaneously as an acne antagonist.

Applications

Unspecified application

Species

Unspecified reactive species

Zijian Su,Yibo Zhang,Jieqiong Cao,Yuanmeng Sun,Yuling Cai,Bihui Zhang,Liu He,Zilei Zhang,Junye Xie,Qilin Meng,Lin Luo,Fu Li,Jingsheng Li,Jinting Zhang,Xiaojia Chen,An Hong

Frontiers in oncology 12:849242 PubMed35646665

2022

A Novel and Robust Prognostic Model for Hepatocellular Carcinoma Based on Enhancer RNAs-Regulated Genes.

Applications

Unspecified application

Species

Unspecified reactive species

Wei Zhang,Kegong Chen,Wei Tian,Qi Zhang,Lin Sun,Yupeng Wang,Meina Liu,Qiuju Zhang

Scientific reports 12:5809 PubMed35388063

2022

AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.

Applications

Unspecified application

Species

Unspecified reactive species

Deepti Reddi,Brandon W Seaton,David Woolston,Lauri Aicher,Luke D Monroe,Zhengwei J Mao,Jill C Harrell,Jerald P Radich,Anjali Advani,Nikolaos Papadantonakis,Cecilia C S Yeung

Frontiers in oncology 12:823491 PubMed35359392

2022

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Jia Zheng,Zhihong Yang,Yanlei Li,Li Yang,Ruili Yao

Archives of toxicology 94:3059-3068 PubMed32588086

2020

Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?

Applications

Unspecified application

Species

Unspecified reactive species

Eva Novotná,Anselm Morell,Neslihan Büküm,Jakub Hofman,Petra Danielisová,Vladimír Wsól

Reproduction (Cambridge, England) 158:493-501 PubMed31671404

2019

Endometrial stromal cell miR-29c-3p regulates uterine contraction.

Applications

Unspecified application

Species

Unspecified reactive species

Lan Xiao,Qiong Zhang,Xi Huang,Aihua He,Shi Xie,Yanping Li
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com